Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXIS R RENTA

Allopathic & Osteopathic Physicians Pain Medicine Interventional Pain Medicine

NPI
1407870736
CMS profile
109676
Location
BOYNTON BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$241.97

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $224.95 5
Travel and Lodging $17.02 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Nevro Corp. $200.45 3
Abbott Laboratories $41.52 3

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXIS R RENTA

NPI 1407870736 · CMS profile ID 109676

Allopathic & Osteopathic Physicians / Pain Medicine / Interventional Pain Medicine

BOYNTON BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407870736?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXIS R RENTA, NPI 1407870736, CMS profile ID 109676. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407870736?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ALEXIS R RENTA, NPI 1407870736, CMS profile ID 109676. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407870736?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ALEXIS R RENTA, NPI 1407870736, CMS profile ID 109676, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1407870736?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $241.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Nevro Corp. $63.5211/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900587065 CMS
Nevro Corp. $17.0207/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900587067 CMS
Nevro Corp. $119.9107/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900587069 CMS
Abbott Laboratories $12.6106/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920462611 CMS
Abbott Laboratories $13.6606/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920462613 CMS
Abbott Laboratories $15.2503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914201211 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $242.99 13
PY2020 $271.41 8
PY2021 $104.65 4
PY2022 $241.97 6
PY2023 $89.81 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $163,161.15 24
PY2024 Principal investigator $664,432.97 41
PY2023 Principal investigator $296,410.62 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,022.34 12/31/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1155803846
Principal investigator 1 SANOFI US SERVICES INC. $3,815.10 12/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712345
Principal investigator 1 SANOFI US SERVICES INC. $5,989.50 12/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712347
Principal investigator 1 SANOFI US SERVICES INC. $1,600.00 12/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712351
Principal investigator 1 SANOFI US SERVICES INC. $150.00 12/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712367
Principal investigator 1 SANOFI US SERVICES INC. $9,633.00 12/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712369
Principal investigator 1 SANOFI US SERVICES INC. $8,087.40 12/03/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712353
Principal investigator 1 SANOFI US SERVICES INC. $3,622.00 12/03/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712357
Principal investigator 1 SANOFI US SERVICES INC. $7,344.00 10/28/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712313
Principal investigator 1 SANOFI US SERVICES INC. $4,279.50 10/21/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712327
Principal investigator 1 SANOFI US SERVICES INC. $1,655.10 10/02/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712307
Principal investigator 1 SANOFI US SERVICES INC. $7,166.00 09/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712303
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,948.60 09/06/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1110848607
Principal investigator 1 SANOFI US SERVICES INC. $6,794.00 08/26/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712299
Principal investigator 1 SANOFI US SERVICES INC. $13,957.80 08/26/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712305
Principal investigator 1 SANOFI US SERVICES INC. $2,625.00 08/12/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712291
Principal investigator 1 SANOFI US SERVICES INC. $2,624.40 07/29/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712295
Principal investigator 1 SANOFI US SERVICES INC. $50.00 07/22/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712289
Principal investigator 1 SANOFI US SERVICES INC. $6,744.00 07/15/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712273
Principal investigator 1 SANOFI US SERVICES INC. $13,788.00 07/15/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712275
Principal investigator 1 SANOFI US SERVICES INC. $16,065.00 07/15/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712281
Principal investigator 1 SANOFI US SERVICES INC. $7,263.90 07/08/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712277
Principal investigator 1 SANOFI US SERVICES INC. $3,327.75 06/17/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712269
Principal investigator 1 SANOFI US SERVICES INC. $15,500.00 06/17/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1128712271
Principal investigator 1 SANOFI US SERVICES INC. $9,499.00 05/06/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712267
Principal investigator 1 AstraZeneca Pharmaceuticals LP $76,282.60 04/24/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1110839330
Principal investigator 1 AstraZeneca Pharmaceuticals LP $19,474.38 04/17/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months No dispute reported 06/30/2026 1110847901
Principal investigator 1 SANOFI US SERVICES INC. $5,152.00 04/15/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712257
Principal investigator 1 SANOFI US SERVICES INC. $10,250.00 03/25/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712253
Principal investigator 1 SANOFI US SERVICES INC. $7,452.00 03/11/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712249
Principal investigator 1 SANOFI US SERVICES INC. $16,731.00 03/04/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712245
Principal investigator 1 SANOFI US SERVICES INC. $3,345.98 02/20/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1128712243
Principal investigator 1 SANOFI US SERVICES INC. $5,657.00 02/12/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712239
Principal investigator 1 SANOFI US SERVICES INC. $11,716.00 02/12/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712241
Principal investigator 1 SANOFI US SERVICES INC. $7,088.00 01/29/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712233
Principal investigator 1 AstraZeneca Pharmaceuticals LP $173,653.82 01/26/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) No dispute reported 06/30/2026 1110839986
Principal investigator 1 AstraZeneca Pharmaceuticals LP $94,944.80 01/24/2024 Non-covered Recipient Entity
HELIX BIOMEDICS, LLC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1110845671
Principal investigator 1 SANOFI US SERVICES INC. $10,324.00 01/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712229
Principal investigator 1 SANOFI US SERVICES INC. $22,628.00 01/16/2024 Non-covered Recipient Entity
Helix Biomedics Llc
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128712231
Principal investigator 1 SANOFI US SERVICES INC. $13,882.00 01/08/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study No dispute reported 06/30/2026 1128712225
Principal investigator 1 SANOFI US SERVICES INC. $300.00 01/08/2024 Non-covered Recipient Entity
Helix Biomedics Llc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1128712227